These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 24591854)

  • 21. Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis.
    Coleman CI; Kreutz R; Sood NA; Bunz TJ; Eriksson D; Meinecke AK; Baker WL
    Am J Med; 2019 Sep; 132(9):1078-1083. PubMed ID: 31054829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion.
    Ezekowitz MD; Cappato R; Klein AL; Camm AJ; Ma CS; Le Heuzey JY; Talajic M; Scanavacca MI; Vardas PE; Kirchhof P; Hohnloser SH; Hemmrich M; Lanius V; Meng IL; Wildgoose P; van Eickels M
    Am Heart J; 2014 May; 167(5):646-52. PubMed ID: 24766973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Chen ST; Hellkamp AS; Becker RC; Berkowitz SD; Breithardt G; Fox KAA; Hacke W; Halperin JL; Hankey GJ; Mahaffey KW; Nessel CC; Piccini JP; Singer DE; Patel MR
    Am J Cardiol; 2017 Nov; 120(10):1837-1840. PubMed ID: 28886856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
    Senoo K; Lip GY
    Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
    Schneeweiss S; Gagne JJ; Patrick AR; Choudhry NK; Avorn J
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):480-6. PubMed ID: 22787066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rivaroxaban for stroke prevention in atrial fibrillation and secondary prevention in patients with a recent acute coronary syndrome.
    Ahrens I; Bode C
    Future Cardiol; 2012 Jul; 8(4):533-41. PubMed ID: 22871192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients.
    Lip GYH; Keshishian A; Li X; Hamilton M; Masseria C; Gupta K; Luo X; Mardekian J; Friend K; Nadkarni A; Pan X; Baser O; Deitelzweig S
    Stroke; 2018 Dec; 49(12):2933-2944. PubMed ID: 30571400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation.
    Chan YH; See LC; Tu HT; Yeh YH; Chang SH; Wu LS; Lee HF; Wang CL; Kuo CF; Kuo CT
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29622587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Role of Nonvitamin K Antagonist Oral Anticoagulants (NOACs) in Stroke Prevention in Patients with Atrial Fibrillation.
    Kuznetsov S; Barcelona R; Josephson RA; Mohan SK
    Curr Neurol Neurosci Rep; 2016 May; 16(5):47. PubMed ID: 27023335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation.
    Turpie AG
    Ther Clin Risk Manag; 2014; 10():197-205. PubMed ID: 24711702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stroke prevention in atrial fibrillation: impact of novel oral anticoagulants.
    Haft JI
    Clin Appl Thromb Hemost; 2013 Jun; 19(3):241-8. PubMed ID: 22952215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease.
    Lopes RD; Steffel J; Di Fusco M; Keshishian A; Luo X; Li X; Masseria C; Hamilton M; Friend K; Gupta K; Mardekian J; Pan X; Baser O; Jones WS
    Am J Med; 2018 Sep; 131(9):1075-1085.e4. PubMed ID: 29807001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Clinical Practice: Focus on Rivaroxaban in Stroke Prevention in Patients With Atrial Fibrillation.
    Sanmartín-Fernández M; Marzal-Martín D
    Clin Appl Thromb Hemost; 2017 Oct; 23(7):711-724. PubMed ID: 27624737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Apixaban versus edoxaban for stroke prevention in nonvalvular atrial fibrillation.
    Xiong Q; Lau YC; Lip GY
    J Comp Eff Res; 2015 Aug; 4(4):367-76. PubMed ID: 26274798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Consensus statement: Management of oral anticoagulation for stroke prevention in patients with nonvalvular atrial fibrillation].
    Helms TM; Silber S; Schäfer A; Masuhr F; Palm F; Darius H; Schrör K; Bänsch D; Bramlage P; Hankowitz J; Karle CA; Stargardt T; Weil J; Geller JC
    Herzschrittmacherther Elektrophysiol; 2016 Sep; 27(3):295-306. PubMed ID: 27576696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation.
    Weitz JI; Eikelboom J
    Thromb Haemost; 2016 Jan; 115(2):257-70. PubMed ID: 26466666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation.
    Ment J
    Vasc Health Risk Manag; 2015; 11():317-32. PubMed ID: 26089678
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.